Cellceutix Enrolls Second Group in Phase 2 Trial of IBD Therapy Brilacidin

Cellceutix Enrolls Second Group in Phase 2 Trial of IBD Therapy Brilacidin
Cellceutix has completed enrolling a second cohort of patients with mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS), two forms of inflammatory bowel disease (IBD), in its Phase 2 clinical trial evaluating brilacidin (PMX-30063). Treatment of this group is expected to be complete by the end of February. The open-label, proof-of-concept Phase 2 clinical trial is designed to assess the remission of the condition (its primary endpoint) in 18 adult patients with mild-to-moderate UP/UPS. The trial is composed of three cohorts (six patients per group), with progressive dose escalation by cohort — 50 mg, 100 mg, and 200 mg of brilacidin, respectively. Patients are receiving brilacidin through retention enema once daily a
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *